6.19
0.49%
0.03
プレマーケット:
6.06
-0.13
-2.10%
前日終値:
$6.16
開ける:
$6.24
24時間の取引高:
267.83K
Relative Volume:
0.89
時価総額:
$277.24M
収益:
$84.82M
当期純損益:
$-21.43M
株価収益率:
-12.63
EPS:
-0.49
ネットキャッシュフロー:
$-27.23M
1週間 パフォーマンス:
-2.21%
1か月 パフォーマンス:
-25.24%
6か月 パフォーマンス:
-46.59%
1年 パフォーマンス:
-34.01%
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
YMAB を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
6.19 | 277.24M | 84.82M | -21.43M | -27.23M | -0.49 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-11-18 | 開始されました | Oppenheimer | Outperform |
2024-08-16 | 開始されました | Cantor Fitzgerald | Overweight |
2024-06-28 | 開始されました | Truist | Buy |
2023-05-10 | アップグレード | Wedbush | Neutral → Outperform |
2023-04-03 | ダウングレード | Guggenheim | Buy → Neutral |
2023-01-27 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
2023-01-05 | ダウングレード | Cowen | Outperform → Market Perform |
2022-12-02 | ダウングレード | BofA Securities | Buy → Neutral |
2022-10-31 | ダウングレード | JP Morgan | Neutral → Underweight |
2022-10-31 | ダウングレード | Wedbush | Outperform → Neutral |
2022-07-06 | 再開されました | Canaccord Genuity | Buy |
2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
2022-02-03 | 再開されました | Guggenheim | Buy |
2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
2021-11-16 | ダウングレード | JP Morgan | Overweight → Neutral |
2021-05-07 | アップグレード | BofA Securities | Neutral → Buy |
2021-04-23 | 再開されました | Cowen | Outperform |
2021-03-22 | 再開されました | JP Morgan | Overweight |
2021-01-15 | ダウングレード | BofA Securities | Buy → Neutral |
2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
2020-05-05 | 開始されました | Barclays | Overweight |
2020-05-01 | 開始されました | Janney | Buy |
2020-04-29 | 開始されました | Morgan Stanley | Equal-Weight |
2019-12-24 | 開始されました | JP Morgan | Overweight |
2019-11-20 | 開始されました | Guggenheim | Buy |
2019-09-04 | 開始されました | Wedbush | Outperform |
2019-04-01 | 開始されました | H.C. Wainwright | Buy |
2018-10-16 | 開始されました | BTIG Research | Buy |
2018-10-16 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Y Mabs Therapeutics Inc (YMAB) 最新ニュース
Contrasting Lotus Pharmaceuticals (OTCMKTS:LTUS) and Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Barclays PLC Increases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics Releases Corporate Overview PresentationOn January 13, 2025, Y-mAbs Therapeutics, Inc. disclosed a corporate overview presentation on its investor relations website, https://ir.ymabs.com. The presentation is intended for investor - Defense World
Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Y-mAbs Therapeutics Updates on Business and Clinical Trials - TipRanks
Y-mAbs Therapeutics (NASDAQ:YMAB) Given "Buy" Rating at HC Wainwright - MarketBeat
Y-mAbs Therapeutics Announces Business Realignment Plan and Preliminary 2024 Financial ResultsOn January 6, 2025, Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) revealed a business realignment plan aimed at maximizing operational efficiencies. The p - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns Outperform Rating from Wedbush - Defense World
Y-mAbs Therapeutics Announces Strategic Business Realignment - Yahoo Finance
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Outperform" Rating from Wedbush - MarketBeat
Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet - Simply Wall St
Correcting & ReplacingY-mAbs Provides Strategic Business Update and 2025 Priorities - The Manila Times
Y-mAbs Reports $88M Revenue, Restructures with Focus on Radiopharmaceuticals and DANYELZA Growth - StockTitan
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities - Business Upturn
Y-mAbs Therapeutics, Inc. Announces Executive Changes - Marketscreener.com
Y-mAbs Appoints Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit - citybiz
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - The Manila Times
Y-mAbs Strengthens DANYELZA Team with Industry Veteran Doug Gentilcore as Business Unit Head - StockTitan
Y-mAbs Provides Strategic Business Update and 2025 Priorities - The Manila Times
Y-mAbs Therapeutics Hits $88M Revenue Target, Unveils Strategic Split Into Two Business Units - StockTitan
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Buy” by Analysts - Defense World
Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $20.89 - MarketBeat
Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA - Yahoo Finance
When (YMAB) Moves Investors should Listen - Stock Traders Daily
Principal Financial Group Inc. Makes New Investment in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Geode Capital Management LLC - Defense World
Barclays PLC Purchases 56,244 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
(YMAB) Trading Report - Stock Traders Daily
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by State Street Corp - Defense World
State Street Corp Grows Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Y-mAbs Therapeutics to Present at J.P. Morgan Healthcare Conference 2025: Cancer Treatment Innovation Spotlight - StockTitan
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely - Yahoo Finance
(YMAB) Trading Signals - Stock Traders Daily
Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdles - Investing.com Australia
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of “Buy” by Brokerages - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Buy” Rating from HC Wainwright - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Receives "Buy" Rating from HC Wainwright - MarketBeat
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Point72 Asset Management L.P. - MarketBeat
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth - Simply Wall St
Equities Analysts Offer Predictions for YMAB FY2024 Earnings - MarketBeat
Brookline Capital Management Predicts YMAB FY2024 Earnings - Defense World
Intech Investment Management LLC Invests $133,000 in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Trend Tracker for (YMAB) - Stock Traders Daily
Y-mAbs' CD38-SADA Shows Promising Anti-Tumor Results in NHL Treatment at ASH Meeting - StockTitan
United Rentals (URI-N) QuotePress Release - The Globe and Mail
Brookline Capital Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Buy Recommendation - MSN
Y Mabs Therapeutics Inc (YMAB) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):